Cargando…
A phase 3 randomized study evaluating sialic acid extended-release for GNE myopathy
OBJECTIVE: To investigate the efficacy and safety of aceneuramic acid extended-release (Ace-ER), a treatment intended to replace deficient sialic acid, in patients with GNE myopathy. METHODS: UX001-CL301 was a phase 3, double-blind, placebo-controlled, randomized, international study evaluating the...
Autores principales: | Lochmüller, Hanns, Behin, Anthony, Caraco, Yoseph, Lau, Heather, Mirabella, Massimiliano, Tournev, Ivailo, Tarnopolsky, Mark, Pogoryelova, Oksana, Woods, Catherine, Lai, Alexander, Shah, Jinay, Koutsoukos, Tony, Skrinar, Alison, Mansbach, Hank, Kakkis, Emil, Mozaffar, Tahseen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6512882/ https://www.ncbi.nlm.nih.gov/pubmed/31036580 http://dx.doi.org/10.1212/WNL.0000000000006932 |
Ejemplares similares
-
Results from a 3-year Non-interventional, Observational Disease Monitoring Program in Adults with GNE Myopathy
por: Lochmüller, Hanns, et al.
Publicado: (2021) -
Phenotypic stratification and genotype–phenotype correlation in a heterogeneous, international cohort of GNE myopathy patients: First report from the GNE myopathy Disease Monitoring Program, registry portion
por: Pogoryelova, Oksana, et al.
Publicado: (2018) -
GNE genotype explains 20% of phenotypic variability in GNE myopathy
por: Pogoryelova, Oksana, et al.
Publicado: (2019) -
Substantial deficiency of free sialic acid in muscles of patients with GNE myopathy and in a mouse model
por: Chan, Yiumo Michael, et al.
Publicado: (2017) -
GNE myopathy: from clinics and genetics to pathology and research strategies
por: Pogoryelova, Oksana, et al.
Publicado: (2018)